Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To demonstrate the relative bioavailability of Cilostazol 50 mg tablets under fasting conditions.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA) |
|
| 2 | Active Comparator | Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA) | Drug |
| ||
| Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA) |
| Measure | Description | Time Frame |
|---|---|---|
| Bioequivalence based on AUC and Cmax | 9 days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| So Ran Hong, M.D. | Novum Pharmaceutical Research Services | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D017291 | Clarithromycin |
| ID | Term |
|---|---|
| D004917 | Erythromycin |
| D018942 | Macrolides |
| D061065 | Polyketides |
| D007783 | Lactones |
| D009930 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|
| Organic Chemicals |